Therefore, the objective of the present study was to create two isogenic in vitro models of PARPi-resistant ovarian cancer derived from a BRCA1-wildtype (HR-proficient) vs. BRCA1-mutated (HR-deficient) genetic background. This evidence concerns the gene BRCA1 and ovarian cancer.